Publication: Atomistic molecular dynamics simulations of typical and atypical antipsychotic drugs at the dopamine D2 receptor (D2R) elucidates their inhibition mechanism
| dc.contributor.author | Salmas, Ramin Ekhteiari | |
| dc.contributor.author | Yurtsever, Mine | |
| dc.contributor.author | Durdagi, Serdar | |
| dc.contributor.institution | Salmas, Ramin Ekhteiari, Department of Biophysics, Bahçeşehir Üniversitesi, Istanbul, Turkey | |
| dc.contributor.institution | Yurtsever, Mine, Department of Chemistry, İstanbul Teknik Üniversitesi, Istanbul, Turkey | |
| dc.contributor.institution | Durdagi, Serdar, Department of Biophysics, Bahçeşehir Üniversitesi, Istanbul, Turkey | |
| dc.date.accessioned | 2025-10-05T16:18:36Z | |
| dc.date.issued | 2017 | |
| dc.description.abstract | Dopamine D2 receptor (D2R) plays a pivotal role in nervous systems. Its dysfunction leads to the schizophrenia, Parkinson’s diseases and drug addiction. Since the crystal structure of the D2R was not solved yet, discovering of potent and highly selective anti-psychotic drugs carry challenges for different neurodegenerative diseases. In the current study, we modeled the three-dimensional (3D) structure of the D2R based on a recently crystallized structure of the dopamine D3 receptor. These two receptors share a high amino acid sequence homology (>70%). The interaction of the modeled receptor with well-known atypical and typical anti-psychotic drugs and the inhibition mechanisms of drugs at the catalytic domain were studied via atomistic molecular dynamics simulations. Our results revealed that, class-I and class-II forms of atypical and typical D2R antagonists follow different pathways in the inhibition of the D2Rs. © 2017 Elsevier B.V., All rights reserved. | |
| dc.identifier.doi | 10.1080/07391102.2016.1159986 | |
| dc.identifier.endpage | 754 | |
| dc.identifier.issn | 07391102 | |
| dc.identifier.issn | 15380254 | |
| dc.identifier.issue | 4 | |
| dc.identifier.pubmed | 26923489 | |
| dc.identifier.scopus | 2-s2.0-84962446680 | |
| dc.identifier.startpage | 738 | |
| dc.identifier.uri | https://doi.org/10.1080/07391102.2016.1159986 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14719/12123 | |
| dc.identifier.volume | 35 | |
| dc.language.iso | en | |
| dc.publisher | Taylor and Francis Ltd. michael.wagreich@univie.ac.at | |
| dc.relation.source | Journal of Biomolecular Structure and Dynamics | |
| dc.subject.authorkeywords | Docking | |
| dc.subject.authorkeywords | Dopamine | |
| dc.subject.authorkeywords | Dopamine D2 Receptor (d2r) | |
| dc.subject.authorkeywords | Gpcrs | |
| dc.subject.authorkeywords | Molecular Dynamics | |
| dc.subject.authorkeywords | Typical And Atypical Anti-psychotics | |
| dc.subject.authorkeywords | Aripiprazole | |
| dc.subject.authorkeywords | Chlorpromazine | |
| dc.subject.authorkeywords | Clozapine | |
| dc.subject.authorkeywords | Haloperidol | |
| dc.subject.authorkeywords | Olanzapine | |
| dc.subject.authorkeywords | Quetiapine | |
| dc.subject.authorkeywords | Risperidone | |
| dc.subject.authorkeywords | Ziprasidone | |
| dc.subject.authorkeywords | Antipsychotic Agents | |
| dc.subject.authorkeywords | Dopamine D2 Receptor Antagonists | |
| dc.subject.authorkeywords | Drd2 Protein, Human | |
| dc.subject.authorkeywords | Receptors, Dopamine D2 | |
| dc.subject.authorkeywords | Aripiprazole | |
| dc.subject.authorkeywords | Chlorpromazine | |
| dc.subject.authorkeywords | Clozapine | |
| dc.subject.authorkeywords | Dopamine 2 Receptor | |
| dc.subject.authorkeywords | Dopamine 3 Receptor | |
| dc.subject.authorkeywords | Haloperidol | |
| dc.subject.authorkeywords | Neuroleptic Agent | |
| dc.subject.authorkeywords | Olanzapine | |
| dc.subject.authorkeywords | Quetiapine | |
| dc.subject.authorkeywords | Risperidone | |
| dc.subject.authorkeywords | Ziprasidone | |
| dc.subject.authorkeywords | Dopamine 2 Receptor Blocking Agent | |
| dc.subject.authorkeywords | Drd2 Protein, Human | |
| dc.subject.authorkeywords | Article | |
| dc.subject.authorkeywords | Atomistic Molecular Dynamics Simulation | |
| dc.subject.authorkeywords | Bilayer Membrane | |
| dc.subject.authorkeywords | Conformation | |
| dc.subject.authorkeywords | Crystal Structure | |
| dc.subject.authorkeywords | Drug Protein Binding | |
| dc.subject.authorkeywords | Hydrogen Bond | |
| dc.subject.authorkeywords | Hydrophobicity | |
| dc.subject.authorkeywords | Molecular Dynamics | |
| dc.subject.authorkeywords | Molecular Stability | |
| dc.subject.authorkeywords | Protein Structure | |
| dc.subject.authorkeywords | Sequence Homology | |
| dc.subject.authorkeywords | Three Dimensional Imaging | |
| dc.subject.authorkeywords | Amino Acid Sequence | |
| dc.subject.authorkeywords | Chemistry | |
| dc.subject.authorkeywords | Human | |
| dc.subject.authorkeywords | Amino Acid Sequence | |
| dc.subject.authorkeywords | Antipsychotic Agents | |
| dc.subject.authorkeywords | Dopamine D2 Receptor Antagonists | |
| dc.subject.authorkeywords | Humans | |
| dc.subject.authorkeywords | Hydrogen Bonding | |
| dc.subject.authorkeywords | Molecular Dynamics Simulation | |
| dc.subject.authorkeywords | Receptors, Dopamine D2 | |
| dc.subject.authorkeywords | Sequence Homology, Amino Acid | |
| dc.subject.indexkeywords | aripiprazole | |
| dc.subject.indexkeywords | chlorpromazine | |
| dc.subject.indexkeywords | clozapine | |
| dc.subject.indexkeywords | dopamine 2 receptor | |
| dc.subject.indexkeywords | dopamine 3 receptor | |
| dc.subject.indexkeywords | haloperidol | |
| dc.subject.indexkeywords | neuroleptic agent | |
| dc.subject.indexkeywords | olanzapine | |
| dc.subject.indexkeywords | quetiapine | |
| dc.subject.indexkeywords | risperidone | |
| dc.subject.indexkeywords | ziprasidone | |
| dc.subject.indexkeywords | dopamine 2 receptor blocking agent | |
| dc.subject.indexkeywords | DRD2 protein, human | |
| dc.subject.indexkeywords | Article | |
| dc.subject.indexkeywords | atomistic molecular dynamics simulation | |
| dc.subject.indexkeywords | bilayer membrane | |
| dc.subject.indexkeywords | conformation | |
| dc.subject.indexkeywords | crystal structure | |
| dc.subject.indexkeywords | drug protein binding | |
| dc.subject.indexkeywords | hydrogen bond | |
| dc.subject.indexkeywords | hydrophobicity | |
| dc.subject.indexkeywords | molecular dynamics | |
| dc.subject.indexkeywords | molecular stability | |
| dc.subject.indexkeywords | protein structure | |
| dc.subject.indexkeywords | sequence homology | |
| dc.subject.indexkeywords | three dimensional imaging | |
| dc.subject.indexkeywords | amino acid sequence | |
| dc.subject.indexkeywords | chemistry | |
| dc.subject.indexkeywords | human | |
| dc.subject.indexkeywords | Amino Acid Sequence | |
| dc.subject.indexkeywords | Antipsychotic Agents | |
| dc.subject.indexkeywords | Dopamine D2 Receptor Antagonists | |
| dc.subject.indexkeywords | Humans | |
| dc.subject.indexkeywords | Hydrogen Bonding | |
| dc.subject.indexkeywords | Molecular Dynamics Simulation | |
| dc.subject.indexkeywords | Receptors, Dopamine D2 | |
| dc.subject.indexkeywords | Sequence Homology, Amino Acid | |
| dc.title | Atomistic molecular dynamics simulations of typical and atypical antipsychotic drugs at the dopamine D2 receptor (D2R) elucidates their inhibition mechanism | |
| dc.type | Article | |
| dcterms.references | Ablordeppey, Seth Y.S., Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-Chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one, Bioorganic and Medicinal Chemistry, 16, 15, pp. 7291-7301, (2008), Apweiler, Rolf, The universal protein resource (UniProt) in 2010, Nucleic Acids Research, 38, SUPPL.1, pp. D142-D148, (2009), Arinami, Tadao, A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia, Human Molecular Genetics, 6, 4, pp. 577-582, (1997), Bas, Delphine C., Very fast prediction and rationalization of pKa values for protein-ligand complexes, Proteins: Structure, Function and Bioinformatics, 73, 3, pp. 765-783, (2008), Borroto-Escuela, Dasiel Oscar, Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes, Biochemical and Biophysical Research Communications, 443, 1, pp. 278-284, (2014), Bussi, Giovanni, Accurate sampling using Langevin dynamics, Physical Review E - Statistical, Nonlinear, and Soft Matter Physics, 75, 5, (2007), Chien, Ellen Y.T., Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist, Science, 330, 6007, pp. 1091-1095, (2010), Christopoulos, Arthur, G protein-coupled receptor allosterism and complexing, Pharmacological Reviews, 54, 2, pp. 323-374, (2002), Conn, Peter Jeffrey, Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders, Nature Reviews Drug Discovery, 8, 1, pp. 41-54, (2009), Darden, Thomas A., Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems, Journal of Chemical Physics, 98, 12, pp. 10089-10092, (1993) | |
| dspace.entity.type | Publication | |
| local.indexed.at | Scopus | |
| person.identifier.scopus-author-id | 56338023600 | |
| person.identifier.scopus-author-id | 56067383000 | |
| person.identifier.scopus-author-id | 22955598300 |
